Corilagin

ArtNr	TMO-T3795-1mg
Hersteller	TargetMol
CAS-Nr.	23094-69-1
Menge	1 mg
Quantity options	100 mg 10 mg 1 mg 200 mg 25 mg 50 mg 5 mg
Kategorie	Reagents & Chemicals Molecules
Typ	Molecules
Specific against	other
Purity	0,9983
Citations	1. Wang Z,et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury.
Smiles	O[C@H]1[C@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(O)c(O)c(O)cc3C(=O)O[C@H]1[C@H](O)[C@H](OC(=O)c1cc(O)c(O)c(O)c1)O2
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	inhibitor
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Targets	TLR\|\|\|Apoptosis\|\|\|Antibacterial\|\|\|Reverse Transcriptase\|\|\|Autophagy
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	634, 45
Description	Corilagin has anti-inflammatory activity. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro.Corilagin can enhance the cytotoxicity of both cisplatin and doxorubicin on the Hep3B hepatoma cells.Corilagin has antiviral activity, reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 μg/mL, respectively. Corilagin shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways.Corilagin has antifibrotics property and is potentiated in treating idiopathic pulmonary fibrosis(IPF), attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-κB and TGF-β1 signaling. Solvent:Pyridine, Methanol, Ethanol, etc.
Bioactivity	Corilagin has anti-inflammatory activity. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro.Corilagin can enhance the cytotoxicity of both cisplatin and doxorubicin on the Hep3B hepatoma cells.Corilagin has antiviral activity, reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 ug/mL, respectively. Corilagin shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways.Corilagin has antifibrotics property and is potentiated in treating idiopathic pulmonary fibrosis(IPF), attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-kappaB and TGF-beta1 signaling. Solvent:Pyridine, Methanol, Ethanol, etc.
Pathways	Autophagy\|\|\|Immunology/Inflammation\|\|\|Microbiology/Virology\|\|\|Apoptosis
Receptor	Others

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

TMO-T3795-1mg-datasheet.pdf

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 1 mg

lieferbar

Technische Frage stellen